pre-clinical drug development

Akelos Inc. is an innovative research-based biotechnology/biopharmaceutical clinical company focused on translating innovative science into treatment. It is developing novel non-narcotic (non-opioid) drugs for the treatment of neuropathic pain, with a non-opioid drug candidate in pre-clinical development. Its development efforts focus on the HCN1 ion channel in primary sensory neurons. The company is partially funded by the National Institutes of Health (NIH) and has exclusively licensed intellectual property from Cornell University.

biopharmaceutical researchHCN1 ion channel targetingpatent licensing

AptamiR Therapeutics, Inc. is a US modular biotechnology company executing the pre-clinical development phase of its targeting OligoNucleotide Therapeutic (ONT) drug candidates. It develops microRNA-based therapeutics using a One Drug-Multiple Targets concept, with projects targeting cardiometabolic disorders (obesity, diabetes, MAFLD/MASH) and epithelial ovarian cancer.

in vitro testingin vivo testingmicroRNA-based therapeuticstargeted drug deliveryvirtual outsourced drug research and development

ChemRegen is a regenerative medicine research and development company located in San Diego, California, combining stem cell biology and drug development. Its initial technology is based on work done in collaboration between Dr. Mark Mercola of the Sanford Burnham Research Institute and Dr. John Cashman of the Human BioMolecular Research Institute, who also serves as Chief Operating Officer of ChemRegen. ChemRegen provides design, implementation, and interpretation of pre-clinical regenerative medicine drug development.

drug developmentregenerative medicine researchstem cell biology